Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb